V1RE3 inhibitors pertain to a class of chemical compounds designed to selectively interact with a specific biological target known as V1RE3, which is a receptor or enzyme encoded by a distinct and characteristic gene sequence. The precision of these inhibitors is a result of meticulous molecular engineering that allows them to bind to their target with high affinity, often through a lock-and-key mechanism that involves the formation of non-covalent bonds such as hydrogen bonds, ionic interactions, and hydrophobic effects. By adhering to the active or allosteric sites on the V1RE3 structure, these inhibitors can modulate the function of the receptor or enzyme, which may play a crucial role in certain biochemical pathways. The design of V1RE3 inhibitors is a sophisticated process that often requires a deep understanding of the structure and function of the target molecule, which is typically gained through techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling.
The development of V1RE3 inhibitors is a multifaceted endeavor that involves not just the initial discovery of a potential inhibitory compound but also its refinement to enhance specificity and binding characteristics. Researchers often employ iterative cycles of synthesis and testing, known as structure-activity relationship (SAR) studies, to fine-tune the chemical properties of these compounds. This may involve altering functional groups, chiral centers, or other molecular features to improve the interaction with the V1RE3 target. As a result, V1RE3 inhibitors can exhibit a range of interactions with their target, from reversible to irreversible binding depending on the nature of the chemical moieties involved and the environmental context within which they are operating. The physicochemical properties of these inhibitors, such as solubility, stability, and lipophilicity, are also critical parameters that are optimized during the development process. The ultimate aim of these modifications is to achieve a compound that is highly selective for the V1RE3 receptor or enzyme, thereby affecting the function of this molecular target in a precise and controlled manner.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR (mammalian target of rapamycin). Since V1RE3 is involved in mTOR signaling, rapamycin would lead to the inhibition of V1RE3 by preventing the activation of downstream targets that are critical for V1RE3's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is upstream of the Akt/mTOR pathway. By inhibiting PI3K, this compound indirectly decreases V1RE3 activity by preventing the initiation of the signaling cascade that V1RE3 is involved in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which acts similarly to LY294002. It suppresses the PI3K/Akt/mTOR pathway, thus reducing the activation of V1RE3-dependent processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 indirectly affects V1RE3 function by altering signaling events that lead to V1RE3 activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The inhibition of p38 MAPK can impact the signaling pathways that contribute to V1RE3 activation, thus decreasing its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in stress-activated MAPK pathways. Inhibition of JNK can disrupt signaling that may be required for V1RE3's activation or function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which prevents the activation of the MAPK/ERK pathway, thereby affecting V1RE3 activity indirectly by modulating the signaling environment it operates within. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is a selective ATP-competitive mTOR inhibitor, distinct from rapamycin. It inhibits both mTORC1 and mTORC2 complexes, thereby reducing the activation of pathways in which V1RE3 is implicated. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1 is a potent and selective mTOR inhibitor that can inhibit both mTORC1 and mTORC2. It would decrease V1RE3 activity by disrupting the signaling pathways V1RE3 is part of. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $173.00 $230.00 $275.00 $332.00 | 9 | |
BKM120 is a pan-class I PI3K inhibitor. By targeting PI3K, BKM120 would lead to the inhibition of downstream signaling including the mTOR pathway, which is necessary for V1RE3 activation. |